New Mexico health officials confirmed plans to use state funds to continue covering gender-affirming care for minors after the Trump administration finalized a federal rule ending Medicaid and Children’s Health Insurance Program support for puberty blockers, hormone therapies, and surgical procedures.
As federal regulatory pressure shifts the landscape of pediatric transgender healthcare nationwide—exemplified by hospital systems like NYU Langone Health dissolving youth programs—state-level policy decisions are establishing stark geographic divides in clinical access.
In Plain English: The Clinical Takeaway
- Puberty Blockers: Medications designed to pause adolescent development by suppressing sex hormones (estrogen and testosterone), which can cost up to $25,000 annually without insurance.
- Medicaid Coverage Shift: The Centers for Medicare and Medicaid Services (CMS) finalized a rule prohibiting federal funds from supporting these interventions for minors under 19, effective October 13, though active patients maintain a six-month transition buffer.
- State-Level Continuity: New Mexico’s state-administered Medicaid program, Turquoise Care, intends to bridge the financial gap, preserving coverage for medications while maintaining existing exclusions for surgical procedures under age 18.
Federal Regulatory Action and the New Mexico Policy Response
The U.S. Department of Health and Human Services and CMS issued a final rule terminating federal financial participation for gender-affirming medical interventions within state Medicaid and CHIP frameworks. According to Timothy Fowler, spokesperson for the New Mexico Health Care Authority, the state plans to absorb these costs entirely through local revenues to maintain Turquoise Care benefits. New Mexico’s program currently covers prescribed medications for transgender and gender-nonconforming youth, though surgical interventions remain excluded for minors.
Adrien Lawyer, executive director and co-founder of the Transgender Resource Center of New Mexico, emphasized the critical nature of insurance coverage for pharmaceutical interventions. Without coverage, out-of-pocket expenses for puberty blockers reach prohibitive thresholds, creating immediate barriers to care. State data indicates that approximately 287,397 children were enrolled in New Mexico’s combined Medicaid and CHIP programs as of July, while demographic modeling by the Williams Institute at the UCLA School of Law estimates roughly 4,800 transgender youth aged 13 to 17 reside within the state.
| Entity / Jurisdiction | Policy Action | Effective Date / Status |
|---|---|---|
| Federal CMS / HHS | Finalized rule ending Medicaid/CHIP funding for youth puberty blockers and hormones. | Effective October 13 (six-month grace period for active patients). |
| New Mexico (Turquoise Care) | Committed state funds to maintain existing Medicaid coverage for medical interventions. | Ongoing adaptation to replace federal funding streams. |
| NYU Langone Health | Dissolved the Transgender Youth Health Program and ceased administering medical care to minors. | Implemented following regulatory pressures and executive orders. |
The federal rule builds upon a sequence of executive and regulatory actions initiated in January 2025 aimed at restricting federal support for pediatric gender-affirming medicine. Parallel pressures have affected major academic medical centers. In New York City, NYU Langone Health announced the closure of its Transgender Youth Health Program, citing the evolving regulatory environment. The decision halted new patient intake and cancelled care appointments for individuals under 19, despite conflicting state directives from New York Attorney General Leticia James reminding providers of state anti-discrimination statutes.
Federal employee health programs have experienced comparable restrictions. The U.S. Office of Personnel Management previously adjusted Federal Employee Health Benefits and Postal Service Health Benefits rules to exclude gender-affirming medical treatments for subscribers of all ages, excluding counseling services. This shift prompted a class-action lawsuit filed in a D.C. federal court by anonymous federal workers arguing sex-based discrimination.
References
- Centers for Medicare & Medicaid Services (CMS). Federal Medicaid Regulations and State Health Program Guidance.
- American Academy of Pediatrics. Pediatrics Official Journal: Analysis of Adolescent Endocrinological Care Costs and Access.
- Williams Institute, UCLA School of Law. Demographic Estimates of LGBT Youth Populations in the United States.
- New Mexico Health Care Authority. Turquoise Care Program Enrollment and Policy Reports.
